We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases
Industry
Pharmaceutical Manufacturing, Scientific Research and Development Services, Services
HQ Location
Via Borgogna, 5
Milan, Lombardy 20122, IT
Keywords
binding proteinselective inhibitorstherapeutic targetssevere chronicmanagement and controlcell capabilitiesclinical candidatesfactor bindingclinical productcell mass